Hallmarks of primary headache: part 1 - migraine

Efficacy and safety of rimegepant 75 mg for acute treatment of migraine: a pooled analysis of four randomized, placebo-controlled trials

OBJECTIVE

This pooled analysis of data from four randomizedplacebo-controlled trials summarizes the efficacy and safety of rimegepant foracute treatment of migraine.

METHODS

In all studies, participants were aged ≥18 years and had a ≥ 1-year history of migraine,two to eight migraine attacks of moderate or severe pain intensity per month,and attacks lasting 4-72 hoursif untreated. Participants were provided a single dose of rimegepant 75 mg orplacebo to treat a single migraine attack of moderate or severe pain intensitywithin the next 45 days. Co-primary endpoints at 2 hours post-dose were painfreedom and freedom from the most bothersome symptom (MBS). Treatmentcomparisons utilized Mantel-Haenszel risk estimation with stratification bystudy and prophylactic migraine medication use randomization stratum; pvalues are nominal. On-treatment adverse events (AEs) were also assessed.

RESULTS

Overall, 4,895 participants received rimegepant (n = 2,439) orplacebo (n = 2,456). For the co-primary endpoints, the proportions ofparticipants with pain freedom 2 hours post-dose (20.0% vs. 11.8%; p < 0.0001)and MBS freedom 2 hours post-dose (40.2% vs. 29.2%; p < 0.0001) were higherin the rimegepant vs. the placebo group. Rimegepant also demonstratedimprovements over placebo in nearly all secondary and exploratory efficacyendpoints. AEs were reported in 11.1% and 9.6% of participants in therimegepant and placebo groups, respectively. The only AE reported in > 1% ofparticipants was nausea (rimegepant = 1.4%, placebo = 1.3%). Severe AEs occurred in0.3% and 0.1% of participants in the rimegepant and placebo groups,respectively. Serious AEs occurred in 0.1% of participants in both groups; nonewere deemed related to study treatment.

CONCLUSION

In this pooled analysis of four randomized placebo-controlledtrials, a single dose of rimegepant 75 mg demonstrated efficacy and a favorablesafety profile for the acute treatment of a migraine attack with moderate orsevere pain.

Menopause, Perimenopause, and Migraine: Understanding the Intersections and Implications for Treatment

Migraine affects women three times more often than it does men, and various mechanisms may explain this incidence, including the key role of female sex hormones. Fluctuations in the levels of these hormones and their feedback control regulate the menstrual cycle, pregnancy, puerperium, perimenopause, and menopause. They can influence the occurrence and severity of migraine throughout the reproductive period. Of particular importance seems to be the perimenopausal period, which is associated with an increase in migraine, especially menstrual migraine, which is considered more disabling and less amenable to treatment than non-menstrual attacks. This article reviews the available evidence documenting the relationship between perimenopause, menopause, and migraine and diagnostic considerations in an attempt to determine the management of these periods of a woman's life. Special considerations, future directions, and unmet needs for perimenopausal and menopausal migraine are also discussed.

Effect of Anodal Transcranial Direct Current Stimulation on the Intensity of Post-dural Puncture Headache: Results of Two Randomized Sham Controlled Trials

INTRODUCTION

Post-dural puncture headache (PDPH) is a common complication of diagnostic lumbar puncture (LP), often leading to extended hospitalization and additional medication use. Clinical studies have shown that anodal transcranial direct current stimulation (a-tDCS) is effective against migraine, and thus we decided to assess whether a-tDCS was also effective in treating and preventing PDPH.

METHODS

In two independent, randomized, monocentric controlled trials (RCTs), we enrolled 97 hospitalized participants who underwent LP for diagnostic purposes. Patients were randomized to receive either active a-tDCS or sham tDCS over the dominant primary motor cortex (M1) in a therapeutic tDCS (Th-tDCS) or preventive tDCS (Pr-tDCS) study. In the two trials, the primary outcome was the severity of PDPH measured using the Visual Analogue Scale (VAS) for pain. Secondary outcomes included the Brief Pain Inventory (BPI) to evaluate other pain-related symptoms associated with LP.

RESULTS

In the Th-tDCS study, significant differences between groups were observed after tDCS in the VAS (F = 17.011, p < 0.001), as well as in BPI intensity (F = 17.006, p < 0.001) and BPI interference (F = 14.730, p < 0.001). Moreover, in the Pr-tDCS study, VAS analysis showed a significant time × group interaction (F = 6.918, p = 0.002). Significant differences were also observed in BPI intensity (F = 17.866, p < 0.001) and BPI interference (F = 15.520, p < 0.001).

CONCLUSIONS

Our findings suggest that a-tDCS may effectively prevent and treat PDPH and alleviate other pain-related symptoms associated with LP. Encouraging results have emerged for the use of a-tDCS in patients undergoing LP, in both experimental research designs (Th-tDCS and Pr-tDCS). A non-invasive brain stimulation (NIBS) technique, such as a-tDCS, could have a therapeutic and preventive effect on pain resulting from a LP.

TRIAL REGISTRATION

ClinicalTrials.gov (ID: NCT06640634) retrospectively registered on October 8, 2024.

Fibroblast reprogramming in the dura mater of NTG-induced migraine-related chronic hypersensitivity model drives monocyte infiltration via Angptl1-dependent stromal signaling

BACKGROUND

Migraine, characterized by recurrent episodes of severe headache, remains mechanistically enigmatic. While traditional theories emphasize trigeminovascular activation, the role of meningeal stromal-immune crosstalk in disease chronicity is poorly understood.

METHODS

A migraine-related chronic hypersensitivity model was utilized via intermittent intraperitoneal nitroglycerin (NTG, 10 mg/kg, every other day for 9 days) and peripheral mechanical hypersensitivity was assessed using von Frey filaments. Single-cell RNA sequencing (scRNA-seq) was performed on dura tissues to construct a cellular atlas of NTG-induced remodeling. These data were then integrated with migraine genome-wide association study (GWAS) risk genes, cell-cell interaction networks, and transcriptional regulation analysis to dissect NTG-driven meningeal remodeling.

RESULTS

The NTG-induced migraine-related chronic hypersensitivity model demonstrated sustained mechanical allodynia, as evidenced by significantly decreased paw withdrawal thresholds (p < 0.0001). Single-cell profiling of the dura mater revealed a 2.4-fold expansion of a pro-inflammatory fibroblast subpopulation (Fibro_c5: 1.9% in Vehicle vs. 4.6% in NTG group), which exhibited marked activation of TNF-α/NF-κB signaling pathways (normalized enrichment score [NES] = 1.83). Concomitantly, we observed an 82% increase in meningeal monocytes (5.7-10.4%) that showed preferential interaction with Fibro_c5 fibroblasts through Angptl1-mediated stromal-immune crosstalk (log2 fold change = 1.41). Regulatory network analysis identified Mafk as the upstream transcriptional regulator orchestrating Angptl1 expression in this pathological communication axis.

CONCLUSION

Our study reveals that NTG reprograms meningeal fibroblasts to expand a pro-inflammatory fibroblast subtype, which drives migraine-related chronic hypersensitivity through TNF-α/NF-κB signaling and Angptl1-mediated monocyte crosstalk. The identified Mafk-Angptl1 axis presents a potential therapeutic target, though human validation remains essential.

Advances in understanding migraine for the development of novel pharmacotherapies: the use of human provocation migraine models

INTRODUCTION

Whilst migraine treatment has advanced significantly over recent times, the mechanisms of attack genesis and heterogeneity in treatment response are two amidst several areas that remain poorly understood and require further development. Experimental migraine provocation is an area that holds promise in advancing this understanding.

AREAS COVERED

We conducted a literature search using PubMed, of 'human migraine triggering' and 'human migraine provocation' to identify articles of interest. We discuss therapeutic targets that have emerged from such work, including calcitonin family peptides (amylin (AMY) and adrenomedullin (ADM)), pituitary adenylate cyclase-activating peptide (PACAP) and potassium channels. We discuss our views on the clinical translation of the outcomes of such studies, and their previous and potential future impact on migraine therapeutics.

EXPERT OPINION

Migraine provocation models provide a valuable means to study human migraine phenotypically and biologically, as well as to assess treatment response. Downstream intracellular mechanisms of provocation agents can be targeted during cellular processing to alter cell function and influence migraine mechanisms. It is important to caveat the clinical translation of provocation studies, given that just because a substance triggers migraine experimentally, does not necessarily mean that the substance is involved in the spontaneous human condition.

Consulting, diagnosis and treatment patterns in migraine: results from the Migraine in Poland cross-sectional survey

Background

The Migraine in Poland study is a cross-sectional survey that assesses symptomatology, consulting, diagnosis, treatment and impact of migraine in Poland.

Objectives

The purpose of this article is to define patterns of care for migraine in Polish patients.

Methods

The survey was conducted from August 2021 to June 2022. Participants were recruited through various channels, targeting mostly persons suffering from headaches. The web survey included questions allowing for diagnosis according to the International Classification of Headache Disorders. A detailed questionnaire evaluated healthcare system utilization, history of diagnosis, as well as the use of acute or preventive treatment, including non-pharmacological methods.

Results

In total, 3225 individuals aged 13-80 (mean age 38.9) responded to the questionnaire (87.1% were women). Migraine without aura (MwoA) diagnosis was confirmed in 1679 (52.7%) of subjects, and 1571 (93.6%) of them consulted a medical professional for their headaches in the past. Among those who consulted for headache, 91% reported having received a medical diagnosis of migraine. 92.5% of MwoA participants declared the current use of some form of treatment. Non-steroidal anti-inflammatory drugs and acetaminophen were the most frequently used acute medications (n = 1318, 78.5%) followed by combination analgesics, especially those containing codeine (n = 991, 59%). Triptans/ergots were used by 57.1%. A total of 22.8% of subjects used acute treatment with a frequency indicating medication-overuse. Prophylactic treatment was at some point used by 35.68%, while 11.49% were currently on preventive medications. The most frequently prescribed preventives were iprazochrome (8.99%), followed by flunarizine (8.10%) and topiramate (5.90%). A total of 23.28% subjects used nutraceuticals for migraine prevention (most frequently magnesium).

Conclusion

Despite high consultation and diagnosis rates among Polish patients with migraine, there is a need for improving standards of care, especially in regard to choice of treatment. There is also a need to raise public awareness of the dangers of codeine-based medications (available over-the-counter in Poland).

Migraine triggers, phases, and classification using machine learning models

Background

In many countries, patients with headache disorders such as migraine remain under-recognized and under-diagnosed. Patients affected by these disorders are often unaware of the seriousness of their conditions, as headaches are neither fatal nor contagious. In many cases, patients with migraine are often misdiagnosed as regular headaches.

Methods

In this article, we present a study on migraine, covering known triggers, different phases, classification of migraine into different types based on clinical studies, and the use of various machine learning algorithms such as logistic regression (LR), support vector machine (SVM), random forest (RF), and artificial neural network (ANN) to learn and classify different migraine types. This study will only consider using these methods for diagnostic purposes. Models based on these algorithms are then trained using the dataset, which includes a compilation of the types of migraine experienced by various patients. These models are then used to classify the types of migraines, and the results are analyzed.

Results

The results of the machine learning models trained on the dataset are verified for their performance. The results are further evaluated by selective sampling and tuning, and improved performance is observed. The precision and accuracy obtained by the support vector machine and artificial neural network are 91% compared to logistic regression (90%) and random forest (87%). These models are run with the dataset without optimal tuning across the entire dataset for different migraine types; which is further improved with selective sampling and optimal tuning. These results indicate that the discussed models are relatively good and can be used with high precision and accuracy for diagnosing different types of migraine.

Conclusion

Our study presents a realistic assessment of promising models that are dependable in aiding physicians. The study shows the performance of various models based on the classification metrics computed for each model. It is evident from the results that the artificial neural network (ANN) performs better, irrespective of the sampling techniques used. With these machine learning models, types of migraines can be classified with high accuracy and reliability, enabling physicians to make timely clinical diagnoses of patients.

Neuromodulation in Chronic Migraine: Evidence and Recommendations from the GRADE Framework

Chronic migraine (CM) affects approximately 2% of the general population and is defined by the persistence of migraine symptoms for at least 15 days per month for at least 3 months. CM is often refractory to common drug treatments and is associated with a significant burden in functions of daily life during ictal phases, productivity loss, and direct costs. Modulation of pain is considered pivotal to reduce its impact and to improve the quality of life among patients with CM. In recent years, neuromodulation in CM has received growing attention; however, there remains no consensus regarding the effectiveness and safety of these procedures. Previous invasive methods such as occipital nerve neurolysis and interruption of the trigeminal dorsal root are not indicated due to high rates of relapsing pain and frequent procedural complications. Although emerging neuromodulation methods, both noninvasive, such as vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS), remote electrical neuromodulation (REM), and invasive, such as deep brain stimulation (DBS), occipital nerve stimulation (ONS), and high-frequency 10-Hz spinal cord stimulation (HF-10 SNS) have demonstrated promising outcomes in early clinical trials, their use has yet to be integrated into routine clinical practice. In this review, study evidence and strength of recommendations are assessed by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. Other conditions such as therapeutic risk/benefit, direct and indirect costs, use of resources, and patient/clinician preferences are also evaluated.

Unveiling new insights into migraine risk stratification using machine learning models of adjustable risk factors

BACKGROUND

Migraine ranks as the second-leading cause of global neurological disability, affecting approximately 1.1 billion individuals worldwide with severe quality-of-life impairments. Although adjustable risk factors-including environmental exposures, sleep disturbances, and dietary patterns-are increasingly implicated in pathogenesis of migraine, their causal roles remain insufficiently characterized, and the integration of multimodal evidence lags behind epidemiological needs.

METHODS

We developed a three-step analytical framework combining causal inference, predictive modeling, and burden projection to systematically evaluate modifiable factors associated with migraine. First, two-sample mendelian randomization (MR) assessed causality between five domains (metabolic profiles, body composition, cardiovascular markers, behavioral traits, and psychological states) and the risk of migraine. Second, we trained ensemble machine learning (ML) algorithms that incorporated these factors, with Shapley Additive exPlanations (SHAP) value analysis quantifying predictor importance. Finally, spatiotemporal burden mapping synthesized global incidence, prevalence, and disability-adjusted life years (DALYs) data to project region-specific risk and burden trajectories through 2050.

RESULTS

MR analyses identified significant causal associations between multiple adjustable factors (including overweight, obesity class 2, type 2 diabetes [T2DM], hip circumference [HC], body mass index [BMI], myocardial infarction, and feeling miserable) and the risk of migraine (P < 0.05, FDR-q < 0.05). The Random Forest (RF)-based model achieved excellent discrimination (Area under receiver operating characteristic curve [AUROC] = 0.927), identifying gender, age, HC, waist circumference [WC], BMI, and systolic blood pressure [SBP] as the predictors. Burden mapping projected a global decline in migraine incidence by 2050, yet persistently high prevalence and DALYs burdens underscored the urgency of timely interventions to maximize health gains.

CONCLUSIONS

Integrating causal inference, predictive modeling, and burden projection, this study establishes hierarchical evidence for adjustable migraine determinants and translates findings into scalable prevention frameworks. These findings bridge the gap between biological mechanisms, clinical practice, and public health policy, providing a tripartite framework that harmonizes causal inference, individualized risk prediction, and global burden mapping for migraine prevention.

Dropout Rate of Participants in Randomized Controlled Trials Using Different Exercise-Based Interventions in Patients with Migraine. A Systematic Review with Meta-Analysis

Background/Objectives: Exercise has gained attention as a potentially beneficial non-pharmacological intervention, but whether this type of intervention presents a higher dropout rate compared to other interventions is still unknown. This systematic review, with a meta-analysis of randomized controlled trials, aims to determine whether exercise or comparators present lower or higher attrition in patients with migraine. Methods: A search was conducted in PubMed, Scopus, Web of Science, and Cochrane Library until March 2025. The methodological quality was evaluated using the JBI scale for randomized trials. Proportion meta-analysis calculated the dropout rate. Results: Odds ratio meta-analysis under 1 indicated lower attrition in experimental participants. Subgroup meta-analyses sorted by type of exercise, control, and migraine were conducted to explore variability in results based on the mentioned moderators. The overall pooled dropout rate was 6.7%, 11.6% for the exercise groups, and 10.1% for the comparators. No statistical difference was found between groups of studies, type of migraine, type of exercise, and type of comparator (p ≥ 0.05). Only the odds ratio results for migraine with auras showed a lower pooled dropout rate in favor of control participants, OR = 1.18. Conclusions: Although there is no statistically significant difference, the meta-analysis of proportions shows a higher loss rate in exercise-based interventions. However, the high heterogeneity found in the included studies prevents us from drawing firm conclusions. Furthermore, adequate adherence to the CONSORT guidelines in reporting losses and their reasons could help design appropriate retention strategies for studies and interventions based on exercise in patients with migraines.

Validation of the Spanish Version of the Headache Impact Test (HIT-6) in Patients With Episodic Migraine

INTRODUCTION

The Headache Impact Test (HIT-6) questionnaire is commonly utilized to assess the impact of headaches in both clinical settings and research. To date, no validated Spanish version of this tool has been published.

OBJECTIVE

This study seeks to evaluate the psychometric properties of the Spanish version of the HIT-6 questionnaire for use in patients experiencing episodic migraine.

METHODS

We conducted a cross-sectional study aimed at validating this measurement instrument. A total of 100 subjects, both male and female, aged 18 to 65 years, diagnosed with episodic migraine, were included in the analysis. Construct validity was assessed using principal component analysis, test-retest reliability via the intraclass correlation coefficient (ICC), internal consistency, and convergent validity against the 12-Item Short Form Health Survey and the Migraine Disability Assessment.

RESULTS

The principal component analysis revealed a two-component structure. The overall HIT-6 scale demonstrated strong test-retest reliability ([ICC = 0.89; 95% CI = 0.83-0.92]), with high reliability for the indirect subscale [(ICC = 0.87; 95% CI = 0.81-0.91)] and excellent reliability for the direct subscale [(ICC = 0.90; 95% CI = 0.85-0.93)]. Internal consistency was also robust (Cronbach's α = 0.834), and the questionnaire showed a significant correlation with MIDAS (r = 0.512; p < 0.001), as well as a moderate correlation with the physical (r = -0.326; p < 0.05) and mental factors (r = -0.429; p < 0.001) of the SF-12.

CONCLUSIONS

The Spanish adaptation of the HIT-6 questionnaire is a reliable and valid tool for evaluating the impact of episodic migraine on patients' quality of life, confirming the validity of both subscales.

Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment

Migraine, a significant cause of disability worldwide, heavily impacts daily functioning and quality of life. Despite various acute treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans, patients experience limited relief or adverse effects. This review examines the efficacy and safety of gepants - ubrogepant, rimegepant, and zavegepant - in the acute treatment of migraine. We assessed phase II and III clinical trials, focusing on clinically relevant endpoints such as pain freedom and freedom from the most bothersome symptom at two hours post-treatment. We calculated the number needed to treat (NNT) to achieve significant endpoints for each gepant. Gepants are recommended for the acute treatment of migraine in individuals who do not respond to triptan monotherapy or combination therapy, who experience only partial effectiveness, or who cannot tolerate or have contraindications to triptans. The NNT values for achieving pain freedom at two hours were 9 for rimegepant, 11 for zavegepant, and 12 for ubrogepant, which are comparable to NSAIDs such as naproxen (NNT = 11). Paracetamol, although not an NSAID, showed similar efficacy (NNT = 12). Triptans demonstrated lower NNTs, indicating higher efficacy. Gepants offer effective, well-tolerated alternatives with no significant cardiovascular risk and minimal potential for medication-overuse headache.

Identifying signals of disproportionate reporting for calcitonin gene-related peptide inhibitors: real-world evidence from the FDA adverse event reporting system

BACKGROUND

Calcitonin gene-related peptide (CGRP) inhibitors have been FDA-approved for migraine prophylaxis and relief. However, their safety profile remains uncertain. This study analyzes adverse events (AEs) and signals of disproportionate reporting (SDRs) using the FDA Adverse Event Reporting System (FAERS).

RESEARCH DESIGN AND METHODS

We analyzed FAERS reports from approval through Q2 2023, standardizing terms using preferred terminology and system organ class (SOCs) classifications. Disproportionality analyses (ROR, PRR, IC) identified SDRs and inclusion in FDA prescribing information was reviewed. Additional analyses included comparisons with other migraine drugs, indication-based sensitivity analyses and causality assessment using the Bradford Hill framework.

RESULTS

Galcanezumab showed strong signals for underdose (ROR 47.4; 95% CI 43.79-51.3), alopecia (5.72; 5.09-6.43), and constipation (6.01; 5.35-6.75), while fremanezumab exhibited notable associations with alopecia (6.9; 5.72-8.33) and weight increased (6.34; 5.18-7.76). Among gepants, rimegepant was linked to somnolence (4.52; 3.57-5.73) and dizziness (3.73; 3.15-4.42) and atogepant showed a strong signal for therapy interruption (16.58; 12.86-21.38).

CONCLUSIONS

This study highlights CGRP inhibitor-associated AEs, underscoring the need for clinical monitoring and risk identification. Early detection of AEs and SDRs can inform protective measures to enhance patient safety.

Migraine and increased cardiovascular disease risk: interaction with traditional risk factors and lifestyle factors

BACKGROUND

Migraine has been linked to a heightened risk of cardiovascular disease, and acute treatment drugs, such as triptans, might increase this risk. This study aimed to determine whether the elevated cardiovascular risk is primarily attributable to the underlying migraine condition or the treatment modalities utilized. Additionally, we investigated the effects of managing traditional cardiovascular risk factors and the influence of healthy lifestyle scores on this association.

METHODS

This population-based investigation leveraged data from the UK Biobank, encompassing participants recruited between 2006 and 2010, to examine the association between migraine and the long-term risk of atherosclerotic cardiovascular disease and its subtypes. Cox proportional hazard models were employed to conduct this analysis. Furthermore, the study evaluated the relative importance of migraine in predicting atherosclerotic cardiovascular disease by calculating the R² values of the Cox models. Additionally, multiplicative and additive interaction analyses were conducted to examine whether the association between migraine and cardiovascular disease varies based on the degree of risk factor control and lifestyle scores.

RESULTS

Across an average follow-up span of 12.9 years, a total of 24,038 cardiovascular events were documented, comprising 12,451 cases of coronary heart disease, 3,608 cases of ischemic stroke, and 4,493 cases of peripheral artery disease. In a thoroughly adjusted analysis, individuals with migraine demonstrated an increased risk of atherosclerotic cardiovascular disease, with a hazard ratio of 1.12 (95% confidence interval: 1.05 to 1.20) compared to those without migraine, indicating a significant trend (PFDR< 0.001). Among female participants under 45 years of age, migraine emerged as a stronger predictor of ASCVD risk than certain lifestyle factors. Furthermore, a significant interaction between migraine and an unhealthy lifestyle was observed in ASCVD risk, evident at both additive and multiplicative levels (P for additive interaction = 0.016; P for multiplicative interaction = 0.041). However, the interactions between migraine and the degree of traditional risk factor control did not reach statistical significance. Additionally, the acute treatment of migraine, including the use of triptans, was not significantly associated with ASCVD risk.

CONCLUSION

A significant interaction exists between unhealthy lifestyles and migraine, where their combined effects may contribute to an elevated risk of cardiovascular diseases, potentially amplifying the impact of each factor. Developing effective lifestyle intervention strategies tailored for migraine patients could help improve their long-term cardiovascular health, emphasizing the importance of comprehensive risk management.

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice

Background/Objectives: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associated with its efficacy. Methods: There are four reasons for prescribing lasmiditan: as an add-on to triptan, if triptan is ineffective, if triptan produces side effects, and when triptan is contraindicated. Lasmiditan was administered at a dose of 50 mg. The efficacy of lasmiditan was defined as the disappearance of headache or a 50% or greater reduction in headache intensity within two hours after dosing. This study included 108 patients with migraines who took lasmiditan. Results: The results for efficacy and the side effects of lasmiditan were as follows: effective without side effects (22), effective with mild side effects (32), ineffective (14), and severe side effects (40). The efficacy rate of lasmiditan 50 mg was 50.0% (54/108). The following factors were found to be associated with lasmiditan's efficacy: sex, migraine classification, calcium channel blockers, and anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment. The overall incidence of side effects was 66.7%, and the dropout rate was 37.0%. Somnolence was more prevalent in the effective group, and other side effects were more prevalent in patients who dropped out due to the side effects of lasmiditan. Conclusions: Lasmiditan is likely to be effective in males with severe migraine classification and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective.

Association between weather conditions and migraine: a systematic review and meta-analysis

BACKGROUND

Previous studies have linked migraine to weather conditions, but variations in the factors examined and inconsistent focus have complicated comparisons. This underscores the need for a more comprehensive and clearer analysis.

METHODS

Studies published before December 2024 on the association between weather and migraine were searched from PubMed, Embase, Web of Science, and Cochrane. Meta-analyses based on effect sizes were performed using Review Manager version 5.4.1.

RESULTS

A total of 31 studies were included in the meta-analyses. It revealed a significant association between migraine attack and weather changes reported as a trigger factor (RD = 0.47, 95% CI = 0.40-0.54). Additionally, specific weather factors, such as temperature (OR = 1.15, 95% CI = 1.02-1.29) and ambient pressure (OR = 1.07, 95% CI = 1.01-1.15), were significantly associated with migraine attacks, while humidity (OR = 1.04, 95% CI = 0.97-1.11) did not show a significant association. Moreover, increased levels of air pollutants, including PM10 (OR = 1.07, 95% CI = 1.03-1.11), PM2.5 (OR = 1.04, 95% CI = 1.01-1.06), NO2 (OR = 1.08, 95% CI = 1.03-1.14), CO (OR = 1.08, 95% CI = 1.01-1.16), and O3 (OR = 1.12, 95% CI = 1.03-1.21), were significantly associated with an increased risk of migraine clinical visits, whereas SO2 (OR = 1.02, 95% CI = 1.00-1.04) was not.

CONCLUSIONS

This meta-analysis revealed that weather changes are significant trigger factors for migraine, with temperature and ambient pressure playing notable roles in this association. Additionally, increased levels of air pollutants are linked to a higher risk of migraine attacks. These findings could lead to new interventions for patients who are weather-sensitive and offer fresh perspectives for future research into the pathogenesis of migraine.

Differences in pharmacological migraine treatment across different levels of clinical headache care - a cross-sectional study

BACKGROUND

Migraine significantly impairs quality of life, reduces workplace productivity, and imposes a substantial socio-economic burden. The severity of migraine correlates with its impact on quality of life and healthcare costs, emphasizing the need for adequate management. In the past, primary care services often faced issues of inadequate treatment. This study evaluates differences in pharmacological recommendations for acute and preventive migraine treatments across primary, secondary, and tertiary care settings.

METHODS

This cross-sectional study involves patients with confirmed migraine (with or without aura) visiting the tertiary headache center at Charité Berlin between 12/2015 and 01/2023 for the first time. Data on headache characteristics and prior treatments for acute and prophylactic treatments at primary/secondary and recommendations from tertiary level of care were retrieved from medical letters written after first consultation.

RESULTS

Among 1,047 migraine patients (42 years, 84% women), 99% had received treatment for acute migraine attacks by primary/secondary care facilities, and 96% were using it at their first consultation, with 63% advised to use a triptan. The average number of triptans tested prior to referral was 1 ± 0.99. Prophylactic treatment was prescribed to 52% of patients by primary/secondary care facilities, with an average of 1.2 ± 1.6 prior prophylactic attempts per patient, and 44% were actively using it at the time of consultation. More than two thirds of patients with over four monthly migraine days were not using prophylactic treatment at referral. Tricyclic antidepressants, beta-blocker and, anticonvulsants were prescribed significantly more often in primary/secondary care settings while Onabotulinumtoxin-A and Calcitonin Gene-Related Peptide(-receptor) antibodies were more commonly initiated in tertiary care. Treatment recommendations from primary/secondary settings were revised in 77% of patients following consultation at the tertiary headache clinic.

CONCLUSION

Compared to previous studies, the overall prescription of acute and prophylactic therapies in primary and secondary care facilities has improved. Further progress is needed in expanding the range of triptans and prophylactic treatments tested before referring patients to specialized centers. However, given the selected study population, the findings may not be fully applicable to all patients treated in primary/secondary care, especially those already receiving adequate care without being referred to specialized settings.

Migraine with and without aura-two distinct entities? A narrative review

Migraine is a primary headache disorder, with a prevalence estimated at approximately 15% globally. According to the International Classification of Headache Disorders, 3rd edition (ICHD3), there are three significant types of migraine: migraine without aura (MO), migraine with aura (MA), and chronic migraine (CM), the former being the most common. Migraine diagnosis is based on official criteria specific to each type. Although a lot is already known about the origin of migraine aura, its pathophysiology is still an object of research.Long-term discussions have been held about MO and MA, with some evidence for the same underlying pathogenesis of both and other arguments against it. In this narrative review, we decided to analyse multiple factors from the perspective of similarities and differences between these two types of migraine. The aim was to understand better the bases underlying both types of migraine.Aspects such as genetics, molecular bases, relation with hormones, epidemiological and clinical features, neuroimaging, neurophysiology, treatment response, and migraine complications are covered to find similarities and differences between MO and MA. Although epidemiology shares similarities for both types, there are slight alterations in sex and age distribution. Genetics and pathogenesis showed some crucial differences. Conditions, such as vestibular symptoms and depression, were found to correlate similarly with both types of migraine. For some features, including increased cardiovascular risk, the tendency appeared to be the same; however, migraine types differ in the strength of correlation. Finally, in cases such as hormones, the influence has shown opposite directions. Therefore, although migraine with and without aura are considered two types of the same disease, more research should focus on their differences, thus finally enabling better specific treatment options for both types of migraine.

High-risk area for migraine attacks - a new concept in migraine pathophysiology

Migraine is a common primary and often disabling neurological disorder, whose pathophysiology is still debated. It does not appear to be an isolated event of head pain but the consequence of recurrent disruption of healthy homeostasis in some brain functions. We propose a new theoretical model, focused on the existence of a "high-risk area" for migraine attacks, which can represent a potential target of non-pharmacologic treatment and prevention. We suggest that migraine arises from the combined effects of three primary factors, namely depressive or unstable mood, unrestful sleep and sympathetic-parasympathetic imbalance with parasympathetic prevalence, alongside with their temporal variability, potentially through dysfunction of homeostatic hypothalamic networks in susceptible individuals. Moreover, these three primary factors contribute to a state of low brain energy, that contains the high-risk area and represents the condition in which migraine attacks rise up. Wearable devices, self-administered questionnaires and clinical tools (i.e., polysomnography, pupillary light reflex, plasma catecholamines dosage) may be used to monitor autonomic nervous system function, mood and sleep and demonstrate the existence of the high-risk area. This will be helpful for patients to understand when they are about to enter in the high-risk area, in order to implement strategies to prevent migraine attacks. This approach would provide a significant advantage in terms of prevention and early treatment.

Revisiting Migraine Pathophysiology: from Neurons To Immune Cells Through Lens of Immune Regulatory Pathways

Migraine is a prevalent neurological disorder characterized by severe, recurrent headaches accompanied by symptoms, such as nausea, photophobia, and phonophobia, significantly affecting the quality of life of millions of people worldwide. Although the neurovascular pathway, involving blood vessel dilation and neurogenic inflammation, has been a cornerstone in understanding migraine pathophysiology. Emerging evidence suggests that immune dysregulation plays a pivotal role in the onset and progression of migraine. This review uniquely synthesizes recent advances linking immune regulatory pathways to migraine, an area that has not been widely explored in the literature. Specifically, we highlighted the involvement of CD4 + CD25 + regulatory T (Treg) cells, interleukins, and pro-inflammatory and anti-inflammatory cytokines, which have been implicated in pain signaling and immune imbalance in patients with migraine. Furthermore, genetic studies have provided compelling evidence by identifying associations between migraine susceptibility and immune-related polymorphisms, particularly in forkhead box P3 (FOXP3) and nuclear factor of activated T cells (NFAT). Moreover, the higher prevalence of migraine in individuals with comorbid autoimmune diseases further supports the hypothesis of a shared pathophysiological mechanism. Despite the growing recognition of immune involvement in migraine, its precise mechanisms remain unclear. By integrating key immune biomarkers and genetic insights, this review proposes a novel framework for understanding the immune-mediated pathways in migraine progression. Future research should focus on elucidating the specific immunological mechanisms underlying migraine, which could open new avenues for innovative, targeted therapeutic strategies.

The burden of migraine in Mexico: a database analysis of migraine-related visits to emergency departments in Mexico's Ministry of Health (MMoH) hospitals

BACKGROUND

The burden of migraine in Mexican Emergency Department (ED) settings remains understudied. This study aimed to determine the frequency of migraine-related ED visits within the ED Mexican Ministry of Health's (MMoH) database and analyze their demographics and treatment patterns.

RESEARCH DESIGN AND METHODS

This retrospective study analyzed MMoH database of ED visits between 2013 and 2022. Visits with migraine diagnosis were selected using ICD-10 codes. Demographic characteristics, geographical location, and time of consultation were described, medication use patterns were analyzed.

RESULTS

Between 2013 and 2022, there were 1,022,450 reported ED visits related to primary headache (0.6% of all ED visits), there were 179,618 migraine-related ED visits (19% of all headache visits). Females represented 78% of visits. Visits peaked in 2014 (20,066) and were the lowest in 2019 (8,273). Medication was used in 21% of visits, NSAIDs being the most frequent (15%). Triptan use was low (0.04% of all migraine visits).

CONCLUSION

Our results highlight the significant burden of migraines on Mexico's healthcare system and the importance of considering age and sex in the approach to migraine ED visits. An update in therapeutic strategies for migraine in Mexico is needed to improve patient outcomes.

Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol

Chronic migraine is a disabling neurovascular disorder that represents the leading cause of years lived with disability in people under 50 with a remarkable social burden due to widespread resistance to the front-line treatments used routinely in current clinical practice. The present study investigates the efficacy and safety of combination therapy using eptinezumab and erenumab, recently approved monoclonal antibodies (mAbs) directed against calcitonin gene-related peptide or its receptor, respectively, or the receptor competitive antagonist atogepant together with botulinum toxin type A in chronic migraine that has proven resistant to front-line treatments for at least 6 weeks. To this aim a retrospective and a prospective phase are designed. Furthermore, a feasible salivary biomarker of migraine is under investigation in the prospective stage of the study. Based on recent expert opinions supporting the switch to easy-to-use small molecule calcitonin gene-related peptide (CGRP)-targeting, i.e. rimegepant or atogepant in unresponsive patients, the present study may offer to clinicians a novel treatment to enhance the therapeutic preventive machinery in chronic migraine.

Internet use May be associated with the severity of headache in migraine patients: results from a Hungarian tertiary headache center

BACKGROUND

Migraine as a prevalent primary headache disorder affects mainly the young population. Migraines worsen the quality of life and are responsible for the main cause of disability worldwide. Apart from the well-known lifestyle factors, the spread of digitalization seems to influence the frequency as well as the severity of migraine attacks, however clinical studies are still lacking. Here we present a prospective single-center cross-sectional study focusing on the possible negative effects of being online and problematic internet use on the severity of headache during migraine attacks taking many covariates into account.

METHODS

Migraine patients were recruited from the Headache Outpatient Clinic of the Department of Neurology, University of Szeged, Szeged, Hungary. Socio-demographic data, medical history of migraine, severity of migraine attacks and details of online activities were recorded as well as online questionnaires focusing on internet addiction.

RESULTS

A total of 192 patients (n = 166 female; n = 26 male) completed the online questionnaire package. After the setup of a logistic regression among socio-demographic data age > 45 years (odds ratio, OR = 1.101), being married (OR = 1.584), number of children > 2 (OR = 1.227), secondary employment (OR = 2.349), while related to being online only nighttime internet use (OR = 1.330) was significantly associated with the severity of migraine attacks.

CONCLUSION

This study is among the first clinical studies focusing on the unfavorable effects of online activities on the severity of headache in migraine patients. Clinicians should be aware the negative effect of being online as a potential non-pharmacological aspect of migraine treatment.

Ubrogepant, erenumab, and eptinezumab antagonize positive inotropic effects of the calcitonin gene-related peptide in the isolated human atrium

The calcitonin gene-related peptide (CGRP) is an endogenous peptide that is known to be involved in the development of a migraine. CGRP is also present in the human heart, acts via CGRP receptors, and has been shown to increase the force of contraction (FOC) in isolated, electrically driven human atrial preparations (HAP) from adult patients obtained during open-heart surgery. Here, the hypothesis was tested that the positive inotropic effect (PIE) of CGRP could be attenuated by three anti-migraine drugs, namely ubrogepant, erenumab (both CGRP receptor antagonists), and eptinezumab (a CGRP antagonist). CGRP, cumulatively applied at concentrations ranging from 1 to 100 nM, increased the FOC. In the presence of cilostamide, an inhibitor of phosphodiesterase III, CGRP was more potent and effective than in the absence of cilostamide. Furthermore, when 100 nM CGRP was administered, subsequent application of ubrogepant (1 nM), erenumab (2 nM), and eptinezumab (6 nM) led to a reduction of FOC in HAP. In a more effective way, 1 µM carbachol and 1 µM (-)-N6-phenylisopropyladenosine (PIA) attenuated the PIE of CGRP in the presence of cilostamide. Conversely, when we applied first ubrogepant (1 nM), erenumab (2 nM), or eptinezumab (6 nM), then, this pre-incubation attenuated the PIE in HAP of cumulatively applied CGRP compared to CGRP given alone. We conclude that ubrogepant, erenumab, and eptinezumab are functional antagonists of CGRP in HAP at therapeutic concentrations of these anti-migraine drugs. Further investigation is necessary to determine whether this reduction in FOC is beneficial or detrimental for migraine patients.

Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 years: a systematic review

BACKGROUND

Migraine patients over 65 years have been excluded from pivotal anti-CGRP monoclonal antibody trials leaving limited real-life data on effectiveness and safety in this population. This review aims to summarize available evidence on treatment response and safety for older patients.

METHODS

A PubMed and Cochrane Controlled Register of Trials (CENTRAL) search identified studies on anti-CGRP monoclonal antibodies in patients with migraine over 65 up to October 2024. The review focuses on headache outcomes like reduction in monthly migraine days or monthly headache days, response rates (30%, 50%, 75%) and adverse effects of this specific population and/or against placebo, standard care, or younger patients. The quality of evidence was assessed using the GRADE tool.

RESULTS

All eligible studies were included, along with additional articles presented narratively. Data from clinical trials and post-hoc analyses show comparable efficacy and safety between older and younger patients. Similarly, early real-life studies support the use of anti-CGRP monoclonal antibodies in patients over 65 years, showing similar response rates, reductions in monthly migraine days and adverse effects.

DISCUSSION

Anti-CGRP monoclonal antibodies should likely be offered to patients over 65 although available evidence remains limited. Further studies analyzing specific data from this subgroup are necessary.

Association Between Dietary Alcohol Intake and Migraine or Severe Headache Miscellaneous Pain: The NHANES 1999-2004

BACKGROUND

The relationship between alcohol consumption and migraine or severe headache remains controversial in the existing literature. Given that alcohol is a widely consumed beverage, clarifying the relationship between alcohol and migraine or severe headaches can help manage the patient's condition.

AIM

This study aimed to investigate the potential relationship between alcohol consumption and migraine or severe headache.

METHODS

Employing National Health and Nutrition Examination Survey (NHANES) database records spanning March 1999 to December 2004, our analysis encompassed threshold effects, smoothed curve fitting, and multivariate logistic regression to elucidate the relationship between alcohol consumption level and migraine or severe headaches. We utilized subgroup analyses and interaction tests to explore the stability of this relationship across different stratified populations.

RESULTS

A total of 13,083 subjects were enrolled. The odds of migraine or severe headache decreased with increasing dietary alcohol intake. This was more pronounced in the older and male subgroups.

CONCLUSIONS

There was a significant negative association between dietary alcohol intake and the odds of having migraine or severe headache.

Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology

INTRODUCTION

Migraine is a disabling neurological disorder with a complex neurobiology. It appears as a cyclic disorder of sensory processing, affecting multiple systems beyond nociception. Overlapping mechanisms, including dysfunctional processing of sensory input from brain structures are involved in the generation of attacks.

AREAS COVERED

This review provides a comprehensive synthesis on migraine neurobiology, which was additionally informed by search of research databases (PubMed, ClinicalTrials.gov). Findings from the most recent literature are integrated in a pathophysiological framework. By combining mechanistic insights and clinical trial data, this review highlights the trajectory of precision medicine in migraine treatment, offering a perspective on the near future of targeted and individualized therapeutic strategies.

EXPERT OPINION

Recent advances in migraine neurobiology offer potential solutions to longstanding challenges. While targeted CGRP therapies have shown promise by addressing specific mechanisms, the pathophysiology of migraine suggests that combination therapies targeting multiple pathways could be beneficial in migraine prevention. The growing diversity of treatment options presents challenges in therapy selection, underscoring the need for predictive biomarkers. These innovations can optimize treatment strategies and improve patient outcomes. As the field progresses, personalized, multimodal approaches are poised to become the standard of care, significantly advancing precision medicine in this area.

Comorbidities as risk factors for migraine onset: A systematic review and three-level meta-analysis

INTRODUCTION

Migraine is a debilitating neurological disease with a multifaceted pathophysiology. Pre-existing comorbidities may influence the risk of developing migraine. This review and meta-analysis aim to present a comprehensive overview of the known comorbidities predisposing individuals to new migraine onset, thereby improving our understanding of the respective diseases' interactions.

METHODS

A systematic search of PubMed and EMBASE identified studies on pre-existing comorbidities as risk factors for new migraine onset. We performed three-level meta-analyses employing restricted maximum likelihood estimation to calculate pooled risk ratios (pRR). Subgroup and sensitivity analyses were conducted to assess the robustness of the data. Risk of bias (RoB) was assessed with the Quality in Prognostic Studies Tool. This review was pre-registered on Prospero (CRD42024501140).

RESULTS

From a total of 17,330 records, we identified 38 studies, encompassing 124 effect sizes from 58 exposures. Most studies (n = 28, 74%) had a low RoB. Heterogeneity was high (>90%), primarily due to within-study differences (>50%), and was not significantly impacted by moderator tests or the exclusion of outliers. We found significantly increased risks for migraine onset associated with prior atopic conditions [pRR = 1.53 (1.15, 2.03)], psychiatric or psychological disorders [pRR = 2.63 (1.79, 3.85)], sleep disorders [pRR = 1.89 (1.26, 2.85)], and cardiovascular conditions [pRR = 1.72 (1.07, 2.76)].

CONCLUSIONS

Pre-existing atopic, psychiatric, sleep, and cardiovascular conditions are significantly associated with new migraine onset, likely due to shared genetic predisposition and mediating factors like stress and inflammation. Future research should focus on these associations to advance targeted prevention and treatment strategies.

An analysis of the burden of migraine and tension-type headache across the global, China, the United States, India and Japan

Background

Recurrent headaches in headache disorders adversely impact quality of life and job. Migraines and tension-type headache TTH) are the most common primary headaches and a prominent cause of disability globally. However, few research compare headache illness burden in China, India, the United States (US), and Japan.

Methods

Global and Chinese, the US, Indian, and Japanese migraine and TTH incidence, prevalence, and disability-adjusted life years were taken from the GBD database for 1990-2021. The data is studied utilizing decomposition analysis, health inequality research, joinpoint regression model, and Bayesian Average Annual Percentage Change (BAPC) model.

Results

The study found that migraine mostly affects women aged 15-49, while TTH are evenly distributed across gender and age. The worldwide average annual percentage change (AAPC) in disease-adjusted life years (DALYs) for migraine and TTH from 1990 to 2021 was 0.0357, a statistically significant trend (p < 0.001), as determined using joinpoint analysis. China exhibited the quickest rise in migraine and TTH incidence and prevalence, as well as the age-standardized rate (ASR) of DALYs, of the four nations analyzed. The US had the highest value of these indicators. Forecasting models reveal that without policy action, migraine prevalence will grow but TTH prevalence would stay unchanged. Decomposition research showed that population expansion is the major cause of migraines and TTH, which will be slightly alleviated by population aging. Health disparities across economic growth areas lessened between 1990 and 2021, according to the report.

Conclusion

Globally and in China, migraine and TTH incidence and burden have increased since 1990. Migraines are becoming more common in young and middle-aged women, so headache treatment professionals should invest more in patient education to raise awareness and improve self-management to reduce disease burden and medical costs.

Fitness-to-work considerations in the paradigmatic pain condition of headache disorder

Headache disorders are common, including in the working population. Clinicians caring for patients with headache need to be aware of work-related factors as potential causes or triggers of headache disorders, and consider the impact of headache on fitness-to-work, especially in safety-sensitive and decision-critical roles. Such fitness-to-work determination should include individualized consideration of the nature of the headache disorder itself, the pattern of the headache, the impact of sleep deprivation on the headache as it relates to fitness to do shiftwork, medication and substance side effects, fitness-to-work implications of associated medical or psychiatric conditions, and the potential of symptom feigning or malingering for secondary gain. As clinicians often struggle with fitness-to-work determinations, a structured approach to fitness-to-work assessments in headache conditions and other pain conditions would improve clarity for clinicians and increase the quality of care provided to patients, with potential benefits for workplace safety and policy in this arena as well.

fMRI Insights into Visual Cortex Dysfunction as a Biomarker for Migraine with Aura

Migraine with aura (MwA) is a common and severely disabling neurological disorder, characterised by transient yet recurrent visual disturbances, including scintillating scotomas, flickering photopsias, and complex geometric patterns. These episodic visual phenomena significantly compromise daily functioning, productivity, and overall quality of life. Despite extensive research, the underlying pathophysiological mechanisms remain only partially understood. Cortical spreading depression (CSD), a propagating wave of neuronal and glial depolarisation, has been identified as a central process in MwA. This phenomenon is triggered by ion channel dysfunction, leading to elevated intracellular calcium levels and excessive glutamate release, which contribute to widespread cortical hyperexcitability. Genetic studies, particularly involving the CACNA gene family, further implicate dysregulation of calcium channels in the pathogenesis of MwA. Recent advances in neuroimaging, particularly functional magnetic resonance imaging (fMRI), have provided critical insights into the neurophysiology of MwA. These results support the central role of CSD as a basic mechanism behind MwA and imply that cortical dysfunction endures beyond brief episodes, possibly due to chronic neuronal dysregulation or hyperexcitability. The visual cortex of MwA patients exhibits activation patterns in comparison to other neuroimaging studies, supporting the possibility that it is a disease-specific biomarker. Its distinctive sensory and cognitive characteristics are influenced by a complex interplay of cortical, vascular, and genetic factors, demonstrating the multifactorial nature of MwA. We now know much more about the pathophysiology of MwA thanks to the combination of molecular and genetic research with sophisticated neuroimaging techniques like arterial spin labelling (ASL) and fMRI. This review aims to synthesize current knowledge and analyse molecular and neurophysiological targets, providing a foundation for developing targeted therapies to modulate cortical excitability, restore neural network stability, and alleviate the burden of migraine with aura. The most important and impactful research in our field has been the focus of this review, which highlights important developments and their contributions to the knowledge and treatment of migraine with aura.

Association between wine consumption and migraine: a systematic review and meta-analysis of cross-sectional

BACKGROUND

It seems that diet is one of the main triggers of migraine; one of the most studied is alcohol, and also, over the years, red wine has been shown to trigger headaches. Therefore, this systematic review and meta-analysis aims to examine the strength of the association between wine consumption and migraine.

METHODS

In this systematic review and meta-analysis, a search of MEDLINE (via PubMed), Scopus, Cochrane, and Web of Science databases was conducted to assess the association between wine consumption and migraine, covering baseline to December 2023. Pooled Odds Ratio (p-OR) were calculated using the DerSimonian and Laird methods. This study was previously registered in PROSPERO (CRD42024511115). The risk of bias was evaluated using The Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.

RESULTS

Five studies were included in this systematic review, and only four of them were in the meta-analysis. Using the DerSimonian and Laird method, the p-OR for the effect of wine consumption on migraine was 0.63 (95% CI 0.36-1.09). The included studies after the risk of bias assessment showed a moderate risk of bias.

CONCLUSIONS

The findings of this systematic review and meta-analysis indicate that there is no conclusive evidence to support an increased or decreased risk of migraine associated with wine consumption.

Critical reflections on medication overuse headache in patients with migraine: An unsolved riddle in nociception

Migraine chronification very frequently exposes patients to the inevitable risk of excessive symptomatic intake that, in turn, prompts development of medication overuse headache (MOH). The latter further compromises headache severity establishing a vicious cycle of symptomatic intake and relapsing head pain that critically worsens the overall clinical status of patients. A great deal of attention has been focused on MOH pathogenesis, and thanks to preclinical and clinical studies knowledge about this disorder is now remarkably advanced. Still, some open questions remain regarding issues related to the neurobiology and neurochemistry underpinning pain chronification in MOH patients, as well as the remedies capable of interrupting pronociceptive cephalic sensitization and drug overuse. Here, a critical reappraisal of these issues is provided in an attempt to gain deeper insight and promote debate on a pain disorder that still represents a conundrum in the field of nociception.

Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women

BACKGROUND

People with multiple sclerosis (MS) have an increased risk of migraine. However, little is known about migraine and other headaches during the prodromal phase (before MS symptom onset). Our objective was to study the risk of migraine in women with MS before MS onset.

METHODS

A nationwide, prospective cohort study of women participating in the Norwegian Mother, Father, and Child cohort study 1999-2008. The women reported the occurrence of migraine and other headaches prior to or during pregnancy. We identified women who later developed MS through data linkage with national health registries in 2018. We excluded women with an established MS diagnosis (n = 125) and women who had experienced their first clinical symptom of MS, but not yet received an MS diagnosis (n = 91). The reference group comprised all other women in the cohort (n = 85,292). We used logistic regression to estimate adjusted odds ratios (aORs) with 95% confidence intervals (95% CIs).

RESULTS

Two hundred and forty-six women developed MS during follow-up. Of these, 116 women had MS symptom onset after 1-5 years, 92 after 6-10 years, and 38 after 10 years. Migraine was more common among women who developed MS compared to the reference group, 18% vs 11%, aOR 1.6 (1.2-2.3), adjusted for age, smoking, socioeconomic status and overweight. The risk of other headaches was similar for women who developed MS compared to the reference group, 29% vs 27%, aOR 1.1 (0.8-1.4). Migraine was reported by 21 of 116 (18%) women with ≤ 5 years until MS symptom onset (aOR 1.7 [1.1-2.8]) and 19 of 92 (21%) women with 6-10 years until MS symptom onset (aOR 1.9 [1.1-2.8]. Only three of 38 (8%) women with > 10 years until MS symptom onset reported migraine, aOR 0.7 (0.2-2.2).

CONCLUSIONS

Women with MS have increased risk of migraine, but not other headaches, up to a decade before the onset of classical MS symptoms. This supports that migraine can be a symptom of the MS prodrome. Special attention in people with migraine may lead to earlier recognition of MS.